Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $5.12.

A number of analysts recently commented on GUTS shares. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Thursday, June 4th. Wall Street Zen cut shares of Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Craig Hallum assumed coverage on Fractyl Health in a research note on Wednesday, July 1st. They set a “buy” rating and a $4.00 price target on the stock. Finally, Weiss Ratings upgraded Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday.

Insider Buying and Selling

In related news, Director Ian Sheffield purchased 35,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The shares were bought at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the acquisition, the director directly owned 35,000 shares in the company, valued at $25,550. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director William Bradley purchased 68,493 shares of the stock in a transaction on Wednesday, June 10th. The shares were purchased at an average cost of $0.73 per share, with a total value of $49,999.89. Following the transaction, the director owned 84,622 shares of the company’s stock, valued at $61,774.06. This trade represents a 424.66% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 171,493 shares of company stock worth $127,150. 8.52% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GUTS. Bank of America Corp DE increased its holdings in Fractyl Health by 23.5% in the 3rd quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock valued at $141,000 after purchasing an additional 16,856 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Fractyl Health during the second quarter worth about $31,000. Jump Financial LLC acquired a new position in shares of Fractyl Health during the fourth quarter worth about $57,000. FNY Investment Advisers LLC boosted its position in shares of Fractyl Health by 84.3% in the second quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock worth $51,000 after buying an additional 29,920 shares during the period. Finally, Scientech Research LLC purchased a new stake in shares of Fractyl Health in the third quarter worth about $49,000.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $0.78 on Monday. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41. The stock has a fifty day simple moving average of $0.76 and a 200-day simple moving average of $0.65. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $2.44. The company has a market capitalization of $124.16 million, a PE ratio of -0.89 and a beta of 2.32.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. On average, equities research analysts expect that Fractyl Health will post -0.53 earnings per share for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.